Biotechnology News and Research

RSS

Evotec AG announces Closing conditions to acquire DeveloGen

Evotec AG today announced the Closing of the agreement to acquire DeveloGen as announced in detail on 14 July 2010.

2 Sep 2010

BRINAVESS IV granted marketing approval in EU for conversion of recent onset AF to sinus rhythm

MSD and Cardiome Pharma Corp. today announced that the intravenous (IV) formulation of BRINAVESS™ (vernakalant) has been granted marketing approval in the European Union (EU), Iceland and Norway for the conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults.

2 Sep 2010

Mipomersen Phase 3 trial in heFH meets primary, secondary and tertiary endpoints

Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented today at the European Society of Cardiology's Congress 2010 in Stockholm, Sweden. The study met its primary endpoint with a 28 percent reduction in LDL-cholesterol, compared with an increase of 5 percent for placebo (p<0.001). The trial also met all of its secondary and tertiary endpoints.

2 Sep 2010

Cellerant Therapeutics signs contract with BARDA to develop CLT-008 therapy for ARS

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has signed a contract valued at up to $153 million over five years with the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services, to develop CLT-008, a cellular therapy for the treatment of Acute Radiation Syndrome (ARS).

2 Sep 2010

Pfizer enters agreement to acquire FoldRx Pharmaceuticals

Pfizer Inc. and FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company, today announced that they have entered into an agreement under which Pfizer will acquire FoldRx.

2 Sep 2010

Celator Pharmaceuticals raises $20 million in Series D private equity financing

Celator Pharmaceuticals, a privately held pharmaceutical company developing new and more effective therapies to treat cancer based on the company's proprietary technology, today announced that it raised $20 million in a Series D private equity financing.

2 Sep 2010

WPI researchers: Cranberry juice cocktail blocks strain of S. aureus

Expanding their scope of study on the mechanisms of bacterial infection, researchers at Worcester Polytechnic Institute have reported the surprise finding from a small clinical study that cranberry juice cocktail blocked a strain of Staphylococcus aureus (S. aureus) from beginning the process of infection.

2 Sep 2010

TriMark predicts regenerative medicine products will exceed $3 billion in 2010

TriMark Publications, LLC a global leader in the biotechnology, healthcare and life sciences publishing, cites in its newly published Regenerative Medicine Markets report that the global market for regenerative medicine products will exceed $3 billion in 2010 and is expected to reach $4.5 billion by 2014.

2 Sep 2010

Martek Biosciences 2010 third quarter revenue increases 51% to $117.2 million

Martek Biosciences Corporation today announced its financial results for the third quarter of fiscal 2010.

2 Sep 2010

pSivida announces FDA Priority Review status for Iluvien NDA

pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has been notified that the U.S. Food and Drug Administration (FDA) has granted Priority Review status for the New Drug Application (NDA) filed for Iluvien for the treatment diabetic macular edema (DME).

31 Aug 2010

Stromedix's STX-100 receives orphan drug status from FDA for treatment of IPF

Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, announced today that its lead clinical candidate STX-100 has been granted orphan drug status by the U.S. Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis, a debilitating and almost uniformly fatal disease in which patients experience progressive difficulty breathing due to fibrosis (scarring) of the lung.

31 Aug 2010

Medicago included in President's report that examines drugs to prevent spread of infectious diseases

Medicago Inc., a clinical-stage biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that it was included in a report of President Obama's Council of Advisors on Science and Technology entitled "Report to the President on Reengineering the Influenza Vaccine Production Enterprise to Meet the Challenges of Pandemic Influenza", which was released earlier this month. U.S. Health and Human Services Secretary Kathleen Sebelius and other public health officials held a briefing to discuss this report and the $2 billion plan to accelerate the development of drugs and vaccines to prevent the spread of infectious diseases.

31 Aug 2010

Incidence of acute myocardial infarction increases among young Italian women: Study

The incidence of acute myocardial infarction in Italy sharply increased, particularly among young women, between the years 2001 and 2005, according to a comprehensive study funded by the Human Health Foundation, a nonprofit Italian charity for biomedical research and health education in Spoleto, Italy. The results were published in Aging Clinical Experimental Research.

31 Aug 2010

Bioheart's MyoCell adult stem cell therapy shows effective for heart failure patients: Study

Bioheart, Inc., The mission of the Cell Therapy Foundation is to improve public health through the support of effective adult stem cell research and education. The Foundation aims to promote basic and applied knowledge, processes and cell therapies.

31 Aug 2010

American Institute of Biological Sciences and National Association of Biology Teachers announce partnership

The American Institute of Biological Sciences and the National Association of Biology Teachers are pleased to announce a new strategic partnership that will help advance the science and education policy interests of the biological sciences community. Through the arrangement, NABT members will be able to access and utilize a suite of AIBS public policy services and resources.

31 Aug 2010

Advanced Cell Technology updates transdifferentiation plans to enhance regenerative medicine

Advanced Cell Technology, Inc. provides an update today on its plans to utilize its transdifferentiation platform to enhance regenerative medicine.

31 Aug 2010

Ipsen 2010 first half revenue increases to €31.7 million

The Board of Directors of Ipsen, chaired by Jean-Luc Bélingard, met on August 30, 2010 to review the Group's results for the first half 2010, published today

31 Aug 2010

Elan Corporation offers to purchase Senior Fixed Rate Notes due 2013

Elan Corporation, plc announced today that Elan's wholly-owned subsidiaries, Elan Finance public limited company and Elan Finance Corp., commenced an offer to purchase of up to $186,000,000 aggregate principal amount of their 8 7/8% Senior Fixed Rate Notes due 2013 (the "2013 Fixed Rate Notes") and their Floating Rate Notes Due 2013 (the "2013 Floating Rate Notes" together with the 2013 Fixed Rate Notes, the "2013 Notes"),

31 Aug 2010

Origin Agritech 2010 third quarter revenue decreases to $68.07 million

Origin Agritech Limited, a technology focused supplier of crop seeds in China, today announced unaudited financial results for the third quarter ended June 30, 2010. Origin prepares its financial statements in accordance with generally accepted accounting principles (GAAP) of the United States.

31 Aug 2010

Biomagnetics to acquire Lanzhou New Sunshine Plastics Industry

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the signing of a Letter of Intent (LOI) with Lanzhou New Sunshine Plastics Industry LTD. This expected acquisition is the fourth planned acquisition targeted at a share price of US $1.50 for Biomagnetics Diagnostics' common shares.

30 Aug 2010

Biotechnology News and Research

Evotec AG announces Closing conditions to acquire DeveloGen

BRINAVESS IV granted marketing approval in EU for conversion of recent onset AF to sinus rhythm

Mipomersen Phase 3 trial in heFH meets primary, secondary and tertiary endpoints

Cellerant Therapeutics signs contract with BARDA to develop CLT-008 therapy for ARS

Pfizer enters agreement to acquire FoldRx Pharmaceuticals

Celator Pharmaceuticals raises $20 million in Series D private equity financing

WPI researchers: Cranberry juice cocktail blocks strain of S. aureus

TriMark predicts regenerative medicine products will exceed $3 billion in 2010

Martek Biosciences 2010 third quarter revenue increases 51% to $117.2 million

pSivida announces FDA Priority Review status for Iluvien NDA

Stromedix's STX-100 receives orphan drug status from FDA for treatment of IPF

Medicago included in President's report that examines drugs to prevent spread of infectious diseases

Incidence of acute myocardial infarction increases among young Italian women: Study

Bioheart's MyoCell adult stem cell therapy shows effective for heart failure patients: Study

American Institute of Biological Sciences and National Association of Biology Teachers announce partnership

Advanced Cell Technology updates transdifferentiation plans to enhance regenerative medicine

Ipsen 2010 first half revenue increases to €31.7 million

Elan Corporation offers to purchase Senior Fixed Rate Notes due 2013

Origin Agritech 2010 third quarter revenue decreases to $68.07 million

Biomagnetics to acquire Lanzhou New Sunshine Plastics Industry

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News